# A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms

> **NCT01309789** · PHASE1 · COMPLETED · sponsor: **Seagen Inc.** · enrollment: 39 (actual)

## Conditions studied

- Lymphoma, Large-Cell, Anaplastic
- Lymphoma, NK-cell
- Lymphoma, T-cell

## Interventions

- **DRUG:** brentuximab vedotin
- **DRUG:** cyclophosphamide
- **DRUG:** brentuximab vedotin
- **DRUG:** prednisone
- **DRUG:** cyclophosphamide
- **DRUG:** doxorubicin
- **DRUG:** doxorubicin
- **DRUG:** prednisone
- **DRUG:** vincristine

## Key facts

- **NCT ID:** NCT01309789
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2013-04
- **Final completion:** 2017-02-28
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2017-06-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01309789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01309789, "A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01309789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*